Skip to main content
    E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.67
    -0.32 (-2.91%)

    Market Cap: $320.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enanta Pharmaceuticals Inc (ENTA) Financials: Revenue, Profit and Cash Flow

    Updated Aug 10, 2026. Financial statements from company filings, amounts in US dollars.

    Enanta Pharmaceuticals reported revenue of $65.32M for the fiscal year ended Sep 30, 2025, down 3.4% from the year before. That year, net income was -$81.89M with a net margin of -125.4%, operating cash flow was -$19.27M and free cash flow was -$32.17M. The quarter ended Jun 30, 2026 had revenue of $14.36M and net income of -$19.50M.

    Revenue and Margins

    Over the 9 years to Sep 2025, revenue fell from $88.27M, a compound annual decline of 3.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$65.32M-3.4%100.0%-130.7%-125.4%
    Sep 2024$67.64M-14.6%100.0%-179.9%-171.6%
    Sep 2023$79.20M-8.1%100.0%-173.2%-169.0%
    Sep 2022$86.16M-11.2%100.0%-143.7%-141.3%
    Sep 2021$97.07M-20.7%100.0%-112.9%-81.4%
    Sep 2020$122.47M-40.3%100.0%-34.0%-29.5%
    Sep 2019$205.20M-0.7%100.0%17.9%22.6%
    Sep 2018$206.63M+101.0%100.0%42.7%34.8%
    Sep 2017$102.81M+16.5%100.0%23.9%17.2%
    Sep 2016$88.27MN/A100.0%34.9%24.5%
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Revenue$65.32M$67.64M$79.20M$86.16M$97.07M$122.47M$205.20M$206.63M$102.81M$88.27M
    Gross profit$65.32M$67.64M$79.20M$86.16M$97.07M$122.47M$205.20M$206.63M$102.81M$88.27M
    Research and development$106.74M$131.48M$163.52M$164.52M$174.11M$136.76M$142.21M$94.86M$57.45M$40.46M
    Operating income-$85.35M-$121.69M-$137.21M-$123.84M-$109.57M-$41.64M$36.74M$88.33M$24.61M$30.84M
    Net income-$81.89M-$116.05M-$133.82M-$121.75M-$79.00M-$36.17M$46.38M$71.96M$17.71M$21.67M
    EBITDA-$80.22M-$120.42MN/A-$119.62M-$104.15M-$37.54MN/A$89.95M$27.29M$34.04M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$14.36M$17.16M$18.61M$15.13M$18.31M$14.93M$16.96M$14.61M$17.97M$17.05M$18.00M$18.93M
    Gross profit$14.36M$17.16M$18.61M$15.13M$18.31M$14.93M$16.96M$14.61M$17.97M$17.05M$18.00M$18.93M
    Operating income-$17.24M-$11.85M-$11.25M-$18.39M-$18.89M-$24.53M-$23.54M-$29.85M-$24.18M-$32.77M-$34.89M-$31.03M
    Net income-$19.50M-$13.09M-$11.94M-$18.70M-$18.25M-$22.64M-$22.29M-$28.82M-$22.66M-$31.16M-$33.41M-$28.11M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, short-term debt of $33.86M exceeded cash and equivalents by $1.56M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$280.73M$376.65M$462.27M$375.41M$438.79M$486.13M$489.83M$414.23M$326.64M$281.28M
    Current assets$204.34M$299.85M$422.79M$311.71M$319.02M$436.84M$401.85M$380.39M$237.82M$232.16M
    Cash and equivalents$32.30M$37.23M$85.39M$43.99M$57.21M$87.13M$51.23M$63.90M$65.67M$16.58M
    Total liabilities$216.01M$247.84M$245.54M$54.08M$39.36M$30.55M$27.34M$20.55M$24.96M$11.34M
    Short-term debt$33.86M$35.99M$5.28M$2.89M$4.20M$4.26MN/AN/A$79.00K$73.00K
    Long-term debtN/AN/AN/AN/AN/AN/A$1.63M$1.63M$762.00K$159.00K
    Shareholder equity$64.72M$128.81M$216.74M$321.33M$399.43M$455.58M$462.49M$393.68M$301.68M$269.94M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$296.87M$314.70M$329.50M$280.73M$301.03M$322.99M$348.64M$376.65M$398.82M$413.56M$348.64M$462.27M
    Total liabilities$195.80M$198.12M$202.91M$216.01M$221.75M$229.46M$236.83M$247.84M$249.91M$247.44M$236.83M$245.54M
    Cash and equivalents$33.42M$34.93M$37.44M$32.30M$44.81M$60.21M$84.35M$37.23M$35.77M$63.54M$84.35M$85.39M
    Shareholder equity$101.07M$116.59M$126.59M$64.72M$79.28M$93.54M$111.82M$128.81M$148.91M$166.11M$111.82M$216.74M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$19.27M-$78.76M-$103.15M-$84.78M-$70.00M$7.09M$71.42M$29.22M$52.65M$35.81M
    Capital expenditures$12.90M$17.95M$9.06M$2.13M$750.00K$1.45M$5.42M$2.98M$2.51M$4.74M
    Free cash flow-$32.17M-$96.71M-$112.21M-$86.91M-$70.75M$5.64M$66.00M$26.24M$50.15M$31.07M
    Dividends paidN/AN/AN/AN/AN/AN/A$2.66M$0$0$0
    Investing cash flow$40.35M$58.23M-$53.58M$54.90M$36.99M$19.83M-$86.66M-$35.40M-$4.57M-$43.66M
    Financing cash flow-$26.62M-$27.63M$198.13M$20.03M$3.08M$8.98M$2.57M$4.41M$1.02M$2.71M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$9.97M-$7.16M-$11.70M-$6.49M$17.51M-$13.49M-$16.80M-$10.40M-$14.78M-$28.60M-$24.99M-$21.60M
    Capital expenditures$7.00K$15.00K$143.00K$1.46M$155.00K$2.54M$8.74M$8.95M$6.54M$1.67M$787.00K$1.37M
    Free cash flow-$9.98M-$7.17M-$11.84M-$7.95M$17.35M-$16.03M-$25.55M-$19.35M-$21.32M-$30.27M-$25.77M-$22.97M
    Last 12 quarters

    Frequently Asked Questions About ENTA

    What is Enanta Pharmaceuticals' annual revenue?

    Enanta Pharmaceuticals reported revenue of $65.32M for the fiscal year ended Sep 30, 2025.

    How fast is Enanta Pharmaceuticals' revenue growing?

    Revenue was down 3.4% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -8.8%.

    Is Enanta Pharmaceuticals profitable?

    No. Enanta Pharmaceuticals reported net income of -$81.89M for the fiscal year ended Sep 30, 2025, with a net margin of -125.4%.

    How much free cash flow does ENTA generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$19.27M minus capital expenditures of $12.90M produced free cash flow of -$32.17M.

    How much debt does Enanta Pharmaceuticals have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $33.86M and cash and equivalents of $32.30M.